Download PDF
Thromb Haemost 1992; 67(06): 665-671
DOI: 10.1055/s-0038-1648520
Original Articles
Schattauer GmbH Stuttgart

A Soluble Recombinant Factor VIII Fragment Containing the A2 Domain Binds to Some Human Anti-Factor VIII Antibodies that Are not Detected by Immunoblotting

Dorothea Scandella
The Jerome H. Holland Laboratory for the Biomedical Sciences, American Red Cross Blood Services, Rockville, MD, USA
,
Lisa Timmons
The Jerome H. Holland Laboratory for the Biomedical Sciences, American Red Cross Blood Services, Rockville, MD, USA
,
Mora Mattingly
The Jerome H. Holland Laboratory for the Biomedical Sciences, American Red Cross Blood Services, Rockville, MD, USA
,
Norma Trabold
The Jerome H. Holland Laboratory for the Biomedical Sciences, American Red Cross Blood Services, Rockville, MD, USA
,
Leon W Hoyer
The Jerome H. Holland Laboratory for the Biomedical Sciences, American Red Cross Blood Services, Rockville, MD, USA
› Author Affiliations
Further Information

Publication History

Received 04 October 1991

Accepted after revision 24 January 1992

Publication Date:
03 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

Human factor VIII (f VIII) inhibitors are pathologic antibodies that inactivate fVIII. A cDNA clone was modified to encode f VIII amino acid residues 373-740 for expression in a baculovirus vector in insect cells. The encoded protein fragment H2 was produced as a soluble, secreted protein, and it was used to test inhibitor plasmas for the presence of antibodies that were not detected by immunoblotting. Seven of 13 inhibitors that bound, only to the fVIII light chain by immunoblotting also bound to fragment H2 in an immunoprecipitation assay. Thus multi-chain inhibitor reactivity of inhibitors is more frequent than previously reported. One of these inhibitors was shown to share the epitope for other inhibitors that bind to H2 within amino acid residues 373-541 in immunoblotting assays. The sensitive immunoprecipitation assay described allows determination of relative H2 binding capacity of the total IgG and epitope localization of inhibitors that cannot be similarly characterized by immunoblotting.

 

  • References

  • 1 Eaton D, Rodriguez H, Vehar GA. Proteolytic processing of human factor VIII. Correlation of specific cleavages by thrombin, factor Xa, and activated protein C with activation and inactivation of factor VIII coagulant activity. Biochemistry 1986; 25: 505-512
    CrossrefPubMedGoogle Scholar
  • 2 Fulcher CA, Roberts JR, Zimmerman TS. Thrombin proteolysis of purified factor VIII procoagulant protein: correlation of activation with generation of a specific polypeptide. Blood 1983; 61: 807-811
    PubMedGoogle Scholar
  • 3 Fulcher CA, de Graaf Mahoney S, Roberts JR, Kasper CK, Zimmerman TS. Localization of human factor F VIII inhibitor epitopes to two polypeptide fragments. Proc Natl Acad Sci USA 1985; 82: 7728-7732
    CrossrefPubMedGoogle Scholar
  • 4 Scandella D, de Graaf Mahoney S, Mattingly M, Roeder D, Timmons L, Fulcher CA. Epitope mapping of human factor VIII inhibitor antibodies by deletion analysis of factor VIII fragments expressed in Escherichia coli . Proc Natl Acad Sci USA 1988; 85: 6152-6156
    CrossrefPubMedGoogle Scholar
  • 5 Scandella D, Mattingly M, de Graaf S, Fulcher CA. Localization of epitopes for human factor VIII inhibitor antibodies by immunoblot-ting and antibody neutralization. Blood 1989; 74: 1618-1626
    PubMedGoogle Scholar
  • 6 Ware J, Lo M, de Graaf S, Fulcher C. Definition of a minimum length factor VIII polypeptide that mimics human factor VIII inhibitor epitopes. Blood 1989; 74: 132a
    PubMedGoogle Scholar
  • 7 Fulcher CA, Lechner K, de G, Mahoney S. Immunoblot analysis shows changes in factor VIII inhibitor chain specificity in factor VIII inhibitor patients over time. Blood 1988; 72: 1348-1356
    PubMedGoogle Scholar
  • 8 Lubahn BC, Reisner HM. Characterization of a monoclonal antiidiotype antibody to human anti-factor VIII antibodies. Proc Natl Acad Sci USA 1990; 87: 8232-8236
    CrossrefPubMedGoogle Scholar
  • 9 Williams DC, Van Frank RM, Muth WL, Burnett JP. Cytoplasmic inclusion bodies in E. coli producing biosynthetic human insulin proteins. Science 1982; 215: 687-689
    CrossrefPubMedGoogle Scholar
  • 10 Luckow VA, Summers MD. Trends in the development of baculovirus expression vectors. Bio/Technology 1988; 6: 47-55
    CrossrefPubMedGoogle Scholar
  • 11 Rotblat F, Goodall AH, O’Brien DP, Rawlings E, Middleton S, Tuddenham EGD. Monoclonal antibodies to human procoagulant factor VIII. J Lab Clin Med 1983; 101: 736-746
    PubMedGoogle Scholar
  • 12 Steinbuch M, Audran R. The isolation of IgG from mammalian sera with the hid of caprylic acid. Arch Biochem Biophys 1969; 134: 279-284
    CrossrefPubMedGoogle Scholar
  • 13 Lazarchick J, Hoyer LW. Immunoradiometric measurement of the factor VIII procoagulant antigen. J Clin Invest 1978; 62: 1048-1052
    CrossrefPubMedGoogle Scholar
  • 14 Kasper CK, Aledort LM, Counts RB, Edson JR, Fratantoni J, Green D, Hampton JW, Hilgartner MW, Lazerson J, Levine PH, McMillan CW, Pool JG, Shapiro SS, Shulman NR, van Eys J. A more uniform measurement of factor VIII inhibitors. Thromb Diathes Haemorrh 1975; 34: 869-872
    PubMedGoogle Scholar
  • 15 Thorell JE, Johansson BG. Enzymatic iodination of polypeptides with 125I to high specific activity. Biochem Biophys Acta 1971; 251: 363-369
    CrossrefPubMedGoogle Scholar
  • 16 Goding JW. Monoclonal Antibodies: Principles and Practice. Academic Press; Orlando, FL: 1983. pp 230-234
  • 17 Zoller MJ, Smith M. Oligonucleotide-directed mutagenesis of DNA fragments cloned into M13 vectors. In: Methods in Enzymology. Wu R, Grossman L, Moldave K. eds Academic Press; New York: 1983. pp 468-500
    Google Scholar
  • 18 Zagursky RJ, Berman ML. Cloning vectors that yield high levels of single-stranded DNA for rapid DNA sequencing. Gene 1984; 27: 183-191
    CrossrefPubMedGoogle Scholar
  • 19 Taniguchi T, Ohno S, Fujii-Kuriyama Y, Maramatsu M. The nucleotide sequence of human fibroblast interferon cDNA. Gene 1980; 10: 11-15
    CrossrefPubMedGoogle Scholar
  • 20 Smith GE, Ju G, Ericson BL, Moschera J, Lahm H-W, Chizzonite R, Summers MD. Modification and secretion of human interleukin 2 produced in insect cells by a baculovirus expression vector. Proc Natl Acad Sci USA 1985; 82: 8404-8408
    CrossrefPubMedGoogle Scholar
  • 21 Summers MD, Smith GE. A Manual of Methods for Baculovirus Vectors and Insect Cell Culture Procedures. Texas Agricultural Experiment Station Bulletin No. 1555. College Station; TX: 1988. 2nd ed..
    Google Scholar
  • 22 Jarvis DL, Summers MD. Glycosylation and secretion of human tissue plasminogen activator in recombinant baculovirus-infected insect cells. Mol Cell Biol 1989; 9: 214-223
    CrossrefPubMedGoogle Scholar
  • 23 Bloom JW. The interaction of rDNA factor VIII, factor VIIIdes_797_1562 and factor VIIIdes-797_i562-derived peptides with phospholipid. Thromb Res 1987; 48: 439-448
    CrossrefPubMedGoogle Scholar
  • 24 Pittman DD, Wang JH, Michnick DA, Fass DN, Kaufman RJ. Identification and functional importance of tyrosine-sulfate residues within human recombinant factor VIII. Blood 1990; 76: 433 a
    PubMedGoogle Scholar
  • 25 Mikkelsen J, Thomsen J, Ezban M. Heterogeneity in the tyrosine sulfation of Chinese hamster ovary cell produced recombinant FVIII. Biochemistry 1991; 30: 1533-1537
    CrossrefPubMedGoogle Scholar
  • 26 Schein CH. Solubility as a function of protein structure and solvent components. Bio/Technology 1990; 8: 308-317
    CrossrefPubMedGoogle Scholar
  • 27 Fulcher CA, de Graaf Mahoney S, Zimmerman TS. FVIII inhibitor IgG subclass and FVIII polypeptide specificity determined by immunoblotting. Blood 1987; 69: 1475-1480
    PubMedGoogle Scholar
  • 28 Eaton DL, Vehar GA. Factor VIII structure and proteolytic processing. In: Progress in Hemostasis and Thrombosis. Collen BS. ed. Grune & Stratton; Orlando, FL, USA: pp 47-70
    Google Scholar